Although the ability of herpes simplex virus (HSV) to establish long term latency is sensory ganglion neurons is well documented, the virus-host interactions involved in transcriptional control of viral genes during latency remain largely unknown. Two latency active promoters have been discovered in the LAT region of the genome. LAP1 contains a TATA box while LAP2 is TATA-less. Reports indicate that LAP1 expresses a large unstable polyA+ 8.7kb transcript from which a small stable 2.0kb polyA- LAT RNA is derived by splicing. Moreover, numerous less abundant LATs of unknown origin have been described. Recent evidence, however, suggests that the 2kb LAT is a primary transcript and associated with polyribosomes. Our laboratory has evidence that LAP2 functions to express reporter genes in both the LAT and an ectopic locus. Experiments are described in the following three interrelated aims to carefully (i) determine whether one or both LAPs express LATs and under what circumstances, (ii) define the cis and trans elements which determine LAP activity and (iii) examine the potential role of chromatin structure in governing latency gene expression. (1) The question of whether LAP1 or LAP2 drive expression of either the major or minor LATs during lytic infection in vitro and during latent infection of the mouse trigeminal ganglion will be addressed through careful examination of transcript termini and through the use of mutants altered in LAP regulatory elements and putative LAT splice donor/acceptor sites. (2) Depending on the outcome of experiments in Aim 1, genetic studies involving recombinant viruses carrying linker-scanner and site-directed mutations in one of both LAPs will be conducted to determine the cis-acting signals that positively and/or negatively regulate LAP function in vitro and in vivo. Biochemical assays are also planned to study the binding of nuclear proteins to specific promoter sequences which contribute to the ability of LAP to function during latency, thereby establishing a connection between LAP functional elements and transcriptional activator or repressor proteins. (3) Studies re outlined to evaluate the role of chromatin structure in governing latency gene expression. The distribution of nucleosomes on latent HSV DNA will be determined by nuclease digestion and correlated with the pattern of gene expression during latency. Additional assays using cell lines carrying chromosomally integrated lytic and latency genes will be employed to evaluate differences between transcriptionally active and silent promoters.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM034534-12A1
Application #
3285710
Study Section
Virology Study Section (VR)
Project Start
1989-09-01
Project End
1997-02-28
Budget Start
1993-03-01
Budget End
1994-02-28
Support Year
12
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Tsvitov, Marianna; Frampton Jr, Arthur R; Shah, Waris A et al. (2007) Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360:477-91
Hong, C-S; Goins, W F; Goss, J R et al. (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-79
Jiang, Canping; Ataai, Mohammad; Ozuer, Ali et al. (2006) Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng 95:48-57
Jiang, Canping; Glorioso, Joseph C; Ataai, Mohammad (2006) Presence of imidazole in loading buffer prevents formation of free radical in immobilized metal affinity chromatography and dramatically improves the recovery of herpes simplex virus type 1 gene therapy vectors. J Chromatogr A 1121:40-5
Moriuchi, Shusuke; Glorioso, Joseph C; Maruno, Motohiko et al. (2005) Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther 12:487-96
Nakano, Kenji; Asano, Ryutaro; Tsumoto, Kouhei et al. (2005) Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 11:617-26
Sasaki, Katsumi; Chancellor, Michael B; Goins, William F et al. (2004) Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 53:2723-30
Niranjan, Ajay; Wolfe, Darren; Tamura, Masakazu et al. (2003) Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 8:530-42
Burton, Edward A; Hong, Chang-Sook; Glorioso, Joseph C (2003) The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells. J Virol 77:3516-30
Moriuchi, S; Wolfe, D; Tamura, M et al. (2002) Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 9:584-91

Showing the most recent 10 out of 46 publications